Free Trial

Iradimed Q2 2024 Earnings Report

Iradimed logo
$60.33 +1.16 (+1.96%)
As of 04:00 PM Eastern

Iradimed EPS Results

Actual EPS
$0.38
Consensus EPS
$0.33
Beat/Miss
Beat by +$0.05
One Year Ago EPS
$0.33

Iradimed Revenue Results

Actual Revenue
$17.93 million
Expected Revenue
$17.70 million
Beat/Miss
Beat by +$230.00 thousand
YoY Revenue Growth
N/A

Iradimed Announcement Details

Quarter
Q2 2024
Time
Before Market Opens

Conference Call Resources

Conference Call Audio

Iradimed Earnings Headlines

IRADIMED Reports Record Revenues for Q4 2024 and Full-Year 2024
Mode Mobile is poised for massive growth and looking to disrupt the $1T+ smartphone industry - Invest Today
While other cell phone carriers are always looking for ways to squeeze every last penny out of their customers, my company pays users for the 40 hours a week they are using smartphone apps, listening to music, and watching videos online with their phones. And you can join us for just $0.26 per share. Plus, when you invest now, you can get up to 100% bonus shares!
Iradimed (IRMD) Gets a Buy from Lake Street
Iradimed Reports Growth In Q4, FY Preliminary Revenues
iRadimed reports preliminary Q4 revenue $19.2M-$19.4M
See More Iradimed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Iradimed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Iradimed and other key companies, straight to your email.

About Iradimed

Iradimed (NASDAQ:IRMD) Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

View Iradimed Profile

More Earnings Resources from MarketBeat